Gilead & Kite Pharma Unveil Breakthrough Cancer Research at ASCO & EHA 2025

GileadNews: In partnership with Kite Pharma, we are excited to share groundbreaking cancer research at this year’s American Society of Clinical Oncology (ASCO) and European Hematology Association (EHA) conferences. Our contribution includes over 20 abstracts, featuring late-breaking findings in first-line metastatic triple-negative breast cancer, updated Phase 2 data on relapsed/refractory multiple myeloma, and early collaborative results on a novel investigational CAR T-cell therapy targeting recurrent glioblastoma.

We remain committed to advancing innovative treatments aimed at improving outcomes for individuals affected by cancer.